Brain Stem Neoplasms

AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that pancreatic cancer patients with high expression levels of either TGFB2, IRF9, or IFI27 showed improvement of median overall survival from 16-20 months to 72 months for patients with low levels of expression for both TGFB2 and either IRF9 or IFI27 validating that knockdown of IRF9 and IFI27 as therapeutic targets for TGFB2 therapeutics. https://www.mdpi.com/3003472 The publications of this series are available at Pubmed as follow: 1) TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. Qazi S, Trieu V. Int J Mol Sci. 2024 Oct 18;25(20):11221. doi: 10.3390/ijms252011221. PMID: 39457004 2) Transforming Growth Factor Beta 2 (TGFB2) mRNA Levels, in Conjunction with Interferon-Gamma Receptor Activation of Interferon Regulatory Factor 5 (IRF5) and Expression of CD276/B7-H3, Are Therapeutically Targetable Negative Prognostic Markers in Low-Grade Gliomas. Trieu V, Maida AE, Qazi S. Cancers (Basel). 2024 Mar 19;16(6):1202. doi: 10.3390/cancers16061202. PMID: 38539537 Free PMC article. 3) Transforming Growth Factor Beta 2 (TGFB2) and Interferon Gamma Receptor 2 (IFNGR2) mRNA Levels in the Brainstem Tumor Microenvironment (TME) Significantly Impact Overall Survival in Pediatric DMG Patients. Qazi S, Talebi Z, Trieu V. Biomedicines. 2024 Jan 15;12(1):191. doi: 10.3390/biomedicines12010191. PMID: 38255296 Free PMC article. 4) High Intra-Tumor Transforming Growth Factor Beta 2 Level as a Predictor of Poor Treatment Outcomes in Pediatric Diffuse Intrinsic Pontine Glioma. Uckun FM, Qazi S, Trieu V. Cancers (Basel). 2023 Mar 9;15(6):1676. doi: 10.3390/cancers15061676. PMID: 36980562 Free PMC article. Additional information on our current phase 3 can be found at: https://www.youtube.com/watch?v=5KqdbySDRKE About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

AGOURA HILLS, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its presentation at Precision in Drug Discovery & Preclinical Summit. Dr. Wen-Han Chang, Nanomedicine Sr. Manager, and Dr. Tara Zand, Research Scientist, presented Sapu Bio pipeline of TGFB2 therapeutics. For additional information please go to: https://events.precision-globe.com/single-event/precision-drug-discovery-preclinical-summit-san-diego##. Dr. Chang and Dr. Zand are experienced nanomedicine and precision drug development dedicated to finding the cure for pancreatic and brain cancers. https://www.linkedin.com/in/wen-han-chang-106002139/ https://www.linkedin.com/in/tara-zand-phd-512042b5/ https://www.linkedin.com/posts/precision-evolution-global-inc_pddpsummit-sandiego-precisionevolutionglobal-activity-7253106596543619072-IqP5/ About Oncotelic Oncotelic (f/k/a Mateon Therapeutics, Inc.), was formed in the State of New York in 1988 as OXiGENE, Inc., was reincorporated in the State of Delaware in 1992, and changed its name to Mateon Therapeutics, Inc. in 2016, and Oncotelic Therapeutics, Inc. in November 2020. Oncotelic is seeking to leverage its deep expertise in oncology drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Oncotelic has rare pediatric designation for Diffuse Intrinsic Pontine Glioma (“DIPG” through OT-101) through its 45% joint venture, GMP Biotechnology Limited, melanoma (through CA4P), and Acute Myeloid Leukemia (through OXi 4503). Oncotelic acquired PointR Data Inc. in November 2019 to build an AI driven biotechnology company. Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each. For more information on AL-101, refer to our Annual Report on Form 10-K/A filed with the SEC on April 19, 2023. Oncotelic's Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as "may", "expect", "anticipate" "hope", "vision", "optimism", "design", "exciting", "promising", "will", "conviction", "estimate," "intend," "believe", "quest for a cure of cancer", "innovation-driven", "paradigm-shift", "high scientific merit", "impact potential" and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company’s product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company’s AI suite including but not limited to AI Chatbots, the public access to the Company’s AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company’s AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the SEC on April 19, 2023 and in the company's other periodic filings. Forward-looking statements are based on expectations and assumptions as of the date of this press release. Except as required by law, the company does not assume any obligation to update forward-looking statements contained herein to reflect any change in expectations, whether because of new information, future events, or otherwise. Contact Information: For Oncotelic Therapeutics, Inc.:Investor Relationsir@oncotelic.com

基因检测,MRD，CTC....确诊癌症后究竟应该做哪些检测？ 近年来，随着生物技术在医学领域的快速发展和人们在细胞分子水平对肿瘤发病机制认识的深入，肿瘤的诊断和治疗已经由经验诊疗时期迈进精准诊疗新时代。从传统病理分型到基于肿瘤及其微环境的基因组学、转录组学、蛋白质组学、表观基因组学和免疫学表征，目前国际和国内有了多种精准检测手段指导癌症治疗，为癌症患者提供了更为个性化、量体裁衣式的干预方案，获得更好的治疗效果，大大降低癌症的发生率和死亡率。 那么跟癌症相关的精准检测都有哪些呢？全球肿瘤医生网医学部将肿瘤为大家详细整理了目前肿瘤精准诊疗检测的常见方法，给病友们参考。（大家如果已经做了相关的检测，也可以提交至全球肿瘤医生网医学部进行解读） 一、肿瘤家属及高危人群 ：遗传性肿瘤基因检测 肿瘤的发生是遗传因素和环境因素共同作用的结果。因此，一些癌症确实存有家族遗传聚集现象。一方面家属与患者拥有的生活方式、饮食习惯及环境基本是一致的，甚至可以说是共同享有。另一方面，遗传性肿瘤约占全部肿瘤的1/10。影响肿瘤遗传的易感因素主要有胚系突变、遗传多态性及遗传变异。 国内外权威医学研究表明，遗传性肿瘤具有家族聚集特征 约 5%-10% 的恶性肿瘤 为遗传性肿瘤 50% 的概率会遗传给子女 其中，发生 胚系突变 的人群中， 发生肿瘤的风险要比普通人群 高数十倍或数百 倍！ 男性、女性中13类癌症与遗传性基因相关 遗传性基因检测可以帮助我们了解是否携带某种癌症相关的基因有害突变;通过对相关基因的综合评估，得出某种癌症的患病风险;指导相关突变基因携带者进行癌症风险管理。研究人员将特定基因的突变与 50 多种遗传性癌症综合征相关联，这些疾病可能使个体易患某些癌症。下表为可用于基因检测的最常见的遗传性癌症综合征，每种综合征中突变的基因，以及最常与这些综合征相关的癌症类型。 二、体内出现异常结节是癌症来了？ 癌症超早期诊断三大检测技术 相信有很多病友都遇到这种“尴尬”，体内出现微小结节，因为太小无法穿刺活检确诊，临床医生只能让继续观察，等病灶足够大的时候才能确诊！ 从体内出现第一个癌变细胞，到形成一个米粒大小的病灶需要10年左右，这是最关键的癌前阶段，是治疗的黄金期，如果能在此时发现并干预，治愈几率可达到近100%。然而当肿瘤小于0.5cm时，传统的检查很难确诊，因此，一旦发现确切的病灶，往往为时已晚，肿瘤已经到了中晚期，大大降低了临床“治愈”几率。 近年来，血液检测的发展，完美的弥补了影像学和组织学的诊断“盲点”，对于临床诊断具有非常大的帮助，使得我们能够提前对微小肿瘤病灶进行干预。目前，有三项检测可用于超早期肿瘤的检测。 01 ctDNA（循环肿瘤DNA） 循环肿瘤DNA（ctDNA）来自于肿瘤细胞因坏死、凋亡或主动分泌等原因释放的DNA片段，通过检测ctDNA能够在早期及癌前阶段发现肿瘤的踪迹，在肿瘤早期或超早期的时候就能够发现基因水平的变化，在癌细胞未形成肿瘤组织前将其捕获。从而达到早筛查，早发现，早诊断及早治疗的目的。适合临床相关指标怀疑癌症但无法确诊的人群。 02 CTC（循环肿瘤细胞） CTC（循环肿瘤细胞）检测可以在肿瘤播散早期发现血液中的CTC，比传统CT检查能提早2-6个月观察到肿瘤变化，发出预警信息，发现早期癌症，也能够及时有针对性地指导患者用药，有效控制肿瘤进展及转移。原文链接：“窥血”识癌防复发：肿瘤“捕手”新检测技术竟能从血液中对癌症种子下手！ 03 免疫功能33项监测 每个人体内的免疫细胞水平和状态都是不同的，当免疫监视功能由于各种原因被消弱时，无法识别和消灭体内的癌细胞，就容易发生肿瘤；如果机体免疫监视功能被削弱，人类的肿瘤发病率会大大的提高。免疫功能33项实时检测是通过抽血分析淋巴细胞亚群来检测细胞免疫和体液免疫功能，能够全面反映机体当前的免疫功能、状态和平衡水平，并可以辅助诊断如自身免疫病、免疫缺陷病、恶性肿瘤、血液病、变态反应性疾病等，分析发病机制，观察疗效及检测预后有重要意义。为什么癌症患者都需要做免疫功能实时监测？ 三、个体化量身定制诊疗方案--癌症精准治疗三大检测 随着全球对癌症研究的不断深入，越来越多的精准抗癌新药和新技术问世，足以控制晚期癌症的进展，提高生活质量，延长寿命，甚至让很多生命即将终结的晚期癌症患者奇迹重生！这些先进的治疗手段让癌症治疗突破了过去仅根据经验或病理分型治疗造成的低治愈率的窘境，通过以下更精准的检测，肿瘤患者将获得更好的治疗方案。 01 基因检测 基因检测已成为癌症精准治疗的标准动作！科学家已经鉴定出一组特定的肿瘤DNA变化，因此肿瘤患者不再是仅根据病理分型选择化疗药物，而可以通过基因检测，发现突变位点，为患者制定更加有效，副作用更小的化疗，靶向，免疫治疗方案，以及家族癌症风险评估。 不得不说，一个患者一套方案的个体化诊疗时代已经到来。以下是欧洲医学肿瘤学会（ESMO）最新发布的首部含金量超高的转移性癌症患者二代测序指南，明确指出了各类癌症应检测的靶点，如果大家做了检测，可以将报告发送至全球肿瘤医生网医学部（4006667998）进行解读，匹配可用的抗癌新药。 分子靶点临床可行性量表（ESCAT） 晚期非鳞状非小细胞肺癌 转移性乳腺癌 结直肠癌 前列腺癌 转移性胃癌 胰腺导管腺癌 晚期肝细胞癌 晚期胆管癌 02 生物标记物检测 除了靶向免疫治疗药物，近年来，过继性细胞免疫疗法在实体瘤的特异性靶点，增殖、细胞因子释放等方面已经有了明显改进，越来越多的临床试验开始尝试将细胞疗法用于实体瘤的治疗，研究人员发现了众多可用于实体瘤的生物标记物靶点，晚期实体肿瘤患者迎来更多的新希望！ 想尝试前沿疗法的病友可提交资料至全球肿瘤医生网医学部申请（4006667998）。 Claudin18.2：用于胃癌，胰腺癌等。 间皮素（mesothelin）：用于治疗间皮瘤、胰腺癌、卵巢癌、肺癌； CEA：用于治疗肺癌、结肠癌、胃癌、乳腺癌和胰腺癌； MUC-1：用于治疗肝癌、肺癌、胰腺癌、结肠癌、胃癌; GPC3：用于治疗肝癌; EGFＲvII：用于治疗神经胶质瘤、头颈部肿瘤； B7-H3：用于治疗尤文肉瘤、横纹肌肉瘤、肾母细胞瘤、神经母细胞瘤和髓母细胞瘤以及特别难以治疗的脑干肿瘤（DIPG）； PSMA：用于前列腺癌等 03 新一代药物遴选技术 目前，利用患者自体的肿瘤进行药物筛选，从而帮助制定个体化的治疗方案，是最为行之有效的手段之一。 新一代药物遴选技术，通过手术从癌症病人身上提取少样的肿瘤细胞样本，在实验室中模拟肿瘤细胞体内的营养需求和肿瘤组织中的胞外微环境，实现对肿瘤细胞的快速扩增，并充分保持了细胞的原代特征。进而对肿瘤细胞进行药物敏感性分析，进行高通量药物筛选，所获得的实验结果与体内用药的致性具有良好的相关性，从而指导医院实现精准用药。 四、远离癌症！癌症治疗后监测复发的三大检测 有很多癌症患者的手术很成功，但最后却死在了复发和转移，据统计，有70%·80%的癌症患者是死于复发、转移！那么，癌症患者手术及治疗后有哪些检测手段能及时监测身体状况，避免癌症复发转移的出现，真正实现临床“治愈”呢？ 01 MRD检测 血液检测的动态随访和监测，可以更为精准地发现患者术后复发的趋势和苗头，从而给了我们主动出击、通过辅助治疗预防复发的策略选择，而不仅仅只是守株待兔，等到复发之后再应对。 分子残留病变（MRD），指的是经过治疗后，传统影像学(包括 PET/CT)或实验室方法不能发现，但通过液体活检发现的癌来源分子异常，代表着肿瘤的持续存在和临床进展可能。MRD 是导致肿瘤复发的主要原因之一! MRD检测能够在短时间内评估患者治疗后的肿瘤残留情况，有助于临床医生了解治疗效果。通过检测体内残留的少量癌细胞（这些癌细胞对治疗无反应或耐药），医生可以判断治疗是否彻底，从而优化后续的治疗方案，对于预测癌症复发风险具有重要意义。 02 肠道菌群检测 研究人员发现，每个人体内的菌群数量，种类都是完全不同的。而正常人体内的肠道菌群和癌症患者体内的菌群更是天壤之别。 值得注意的是，癌症疗法（例如化学疗法和放射疗法）可能会破坏肠道菌群。科学家正在研究益生菌是否可以帮助接受癌症治疗的人重新平衡菌群。例如，一些研究表明，益生菌可以减少接受化疗的肺癌患者和接受结肠癌手术的人的腹泻。 肠道菌群检测是精准检测之—，基于二代高通量基因测序技术（16SrDNA）精确反应人体肠道菌群种类、数量、结构，识别疾病风险及健康水平。通过肠道菌群检测的检测可以有效评估大部分的慢病风险和进展，甚至可提前对部分疾病进行预警。同时可以针对癌症患者人群，精确反映肠道菌群结构以及菌群平衡情况，个性化定制养菌、种菌的解决方案，平衡免疫系统，达到改善过敏及自体免疫、提升免疫细胞灭癌能力、防癌抗癌等功能。 因此，肿瘤患者在治疗期间和结束后应进行肠道菌群的检测，看看是否存在肠道菌群失衡，及时进行纠正和调整， 大家可以致电全球肿瘤医生网医学部了解肠道菌群检测及调节方式及获得定制化肠菌调节方案。 03 营养功能检测 根据中国抗癌协会肿瘤营养与知识治疗专委会一项3万多人的调查研究表示，我国发现将近三分之二的患者存在不同程度的营养不良。营养不良会导致患者对治疗耐受性降低、刀口不容易愈合、术后容易发生感染等，直接降低了患者的生活质量，影响治疗效果，甚至生存期因此大打折扣！正常的营养功能是维持机体免疫，抵抗癌症的基础。因此，肿瘤患者应该实时监测自己的营养功能是否正常，一旦发现异常，应该及时干预，进行相应营养支持治疗。 以上适用于各类人群的精准检测手段只是目前众多研发热点中的一小部分，相信更多的创新技术正在路上，终将让癌症无处遁形！